A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED DOSE RANGING TRIAL TO DETERMINE THE SAFETY AND EFFICACY OF THREE DOSE LEVELS OF EMA401 IN REDUCING 24-HOUR AVERAGE PAIN INTENSITY SCORE IN PATIENTS WITH POST-HERPETIC NEURALGIA (EMPHENE)
- Registry ID
- CEMA401A2201
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Start date
- 2018-09-11
- Last update
- 2017-05-10
Conditions
- POST-HERPETIC NEURALGIA (PHN)
View on source registry